You are here

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Los Angeles, California, 90095-6984 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with a histologically or cytologically confirmed malignant solid tumor for
which there is no currently approved treatment or which is unresponsive to currently
approved therapies.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

- Female patients of childbearing potential must have a negative serum or urine
pregnancy test within 72 hours of the first dose of PF-04961502, These patients or
their partners must be surgically sterile or be postmenopausal, or must agree to use
effective contraception while receiving trial treatment and for at least 3 months
thereafter. Male patients or their partners must be surgically sterile or must agree
to use effective contraception while receiving trial treatment and for at least 3
months thereafter. The definition of effective contraception will be based on the
judgment of the Principal Investigator or a designated associate

- Adequate Bone Marrow Function, including:

1. Absolute neutrophil count (ANC) ≥1500 cells/mm3

2. Platelets ≥75,000 cells/mm3

3. Hemoglobin ≥9 mg/dL

- Adequate Renal Function, including:

SrCr calculated using method standard for the institution

- Adequate Liver Function, including:

Bilirubin ≤1.5 x ULN AST (SGOT) ≤2.5 x ULN ALT (SGPT) ≤2.5 x ULN

- Adequate glucose control, including no previous diagnosis of diabetes mellitus and
HbA1c

- Adequate Cardiac Function, including:

12-Lead electrocardiogram (ECG) with normal tracing or non clinically significant
changes that do not require medical intervention. QTc interval ≤470 msec and no
history of Torsades des Pointes or other symptomatic QTc abnormality

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with known active brain metastases. Patients with previously diagnosed brain
metastases are eligible if they have completed their CNS treatment and have recovered
from the acute effects of radiation therapy or surgery prior to the start of study
medication, have discontinued corticosteroid treatment for these metastases for at
least 4 weeks and are neurologically stable

- Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will
not be followed for tumor assessment on this study, ie, non target lesions),
biological or investigational agents within 2 weeks of Baseline disease assessments

- Any surgery (not including minor procedures such as lymph node biopsy) within 4 weeks
of Baseline disease assessments; or not fully recovered from any side effects of
previous procedures

- Prior therapy with an agent that is known or proposed to be active by action on PI3K
and/or mTOR

- Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within
12 months of study treatment start

- Uncontrolled or significant cardiovascular disease:

A myocardial infarction within 12 months Uncontrolled angina within 6 months Congestive
heart failure within 6 months. Diagnosed or suspected congenital long QT syndrome. Any
history of ventricular arrhythmias (such as ventricular tachycardia, ventricular
fibrillation, or Torsades de pointes). Any history of second or third degree heart block
(may be eligible if currently have a pacemaker) Heart rate electrocardiogram Uncontrolled hypertension.

- Current use or anticipated need for food or drugs that are known potent CYP3A4
inhibitors or inducers

- Current use or anticipated need for food or drugs that are known potent CYP1A2
inhibitors or inducers

- Concurrent administration of herbal preparations

- Breast feeding: No studies have been conducted in humans to assess the impact of
PF-04691502 on milk production, its presence in breast milk and its effects on the
breast-fed child. Because drugs are commonly excreted in human milk and because of the
potential for serious adverse reactions in nursing infants, lactating female patients
are excluded from this study.

- Any clinically significant gastrointestinal abnormalities, which may impair intake,
transit or absorption of the study drug, such as the inability to take oral medication
in tablet form and malabsorption syndrome.

- Any mental disorder that would limit the understanding or rendering of informed
consent and/or compromise compliance with the requirements of this protocol

NCT00927823
Pfizer
Completed
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Androgen Receptor Positive Triple Negative Breast Cancer Advanced
NCT01889238
Females
18+
Years
Multiple Sites
Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
NCT02003924
Males
18+
Years
Multiple Sites
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors
A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cancer
Drug: PF-04691502
Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
Experimental: PF-04691502 Treatment
Intervention: Drug: PF-04691502
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
April 2012
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a histologically or cytologically confirmed malignant solid tumor for which there is no currently approved treatment or which is unresponsive to currently approved therapies.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
  • Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours of the first dose of PF-04961502, These patients or their partners must be surgically sterile or be postmenopausal, or must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter. Male patients or their partners must be surgically sterile or must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate
  • Adequate Bone Marrow Function, including:

    1. Absolute neutrophil count (ANC) ?1500 cells/mm3
    2. Platelets ?75,000 cells/mm3
    3. Hemoglobin ?9 mg/dL
  • Adequate Renal Function, including:

SrCr <1.5 x ULN (upper limit of normal). OR Estimated creatinine clearance ?60 mL/min, as calculated using method standard for the institution

  • Adequate Liver Function, including:

Bilirubin ?1.5 x ULN AST (SGOT) ?2.5 x ULN ALT (SGPT) ?2.5 x ULN

  • Adequate glucose control, including no previous diagnosis of diabetes mellitus and HbA1c <7%.
  • Adequate Cardiac Function, including:

    12-Lead electrocardiogram (ECG) with normal tracing or non clinically significant changes that do not require medical intervention. QTc interval ?470 msec and no history of Torsades des Pointes or other symptomatic QTc abnormality

Exclusion Criteria:

  • Patients with known active brain metastases. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable
  • Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, ie, non target lesions), biological or investigational agents within 2 weeks of Baseline disease assessments
  • Any surgery (not including minor procedures such as lymph node biopsy) within 4 weeks of Baseline disease assessments; or not fully recovered from any side effects of previous procedures
  • Prior therapy with an agent that is known or proposed to be active by action on PI3K and/or mTOR
  • Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within 12 months of study treatment start
  • Uncontrolled or significant cardiovascular disease:

A myocardial infarction within 12 months Uncontrolled angina within 6 months Congestive heart failure within 6 months. Diagnosed or suspected congenital long QT syndrome. Any history of ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes). Any history of second or third degree heart block (may be eligible if currently have a pacemaker) Heart rate <50/minute on pre-entry electrocardiogram Uncontrolled hypertension.

  • Current use or anticipated need for food or drugs that are known potent CYP3A4 inhibitors or inducers
  • Current use or anticipated need for food or drugs that are known potent CYP1A2 inhibitors or inducers
  • Concurrent administration of herbal preparations
  • Breast feeding: No studies have been conducted in humans to assess the impact of PF-04691502 on milk production, its presence in breast milk and its effects on the breast-fed child. Because drugs are commonly excreted in human milk and because of the potential for serious adverse reactions in nursing infants, lactating female patients are excluded from this study.
  • Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form and malabsorption syndrome.
  • Any mental disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00927823
B1271001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2014

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now